Entero Healthcare Solutions Ltd
ENTEROEntero Healthcare Solutions Ltd
ENTERO
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 88.94 | 3.87 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast from 3 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Entero Healthcare Solutions is an India-based technology-driven and integrated healthcare products distribution company.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,783.67 | 2,526.55 | 3,305.72 | 3,936.72 | 4,460.19 | |||||
Raw Materials | 1,685.19 | 2,342.47 | 3,051.26 | 3,627.81 | 4,294.43 | |||||
| Power & Fuel Cost | 3.39 | 4.07 | 4.25 | 5.60 | ||||||
| Employee Cost | 75.94 | 114.81 | 128.14 | 151.15 | ||||||
| Selling & Administrative Expenses | 21.31 | 33.75 | 55.19 | 65.24 | ||||||
| Operating & Other expenses | -27.64 | 2.53 | -2.64 | -39.34 | ||||||
EBITDA | 25.48 | 28.92 | 69.52 | 126.26 | 165.76 | |||||
| Depreciation/Amortization | 16.28 | 19.75 | 24.24 | 25.02 | 27.23 | |||||
| PBIT | 9.20 | 9.17 | 45.28 | 101.24 | 138.53 | |||||
| Interest & Other Items | 20.04 | 28.98 | 48.97 | 65.68 | 54.55 | |||||
| PBT | -10.84 | -19.81 | -3.69 | 35.56 | 83.98 | |||||
| Taxes & Other Items | 4.69 | 10.10 | 7.87 | -3.55 | 12.53 | |||||
| Net Income | -15.53 | -29.91 | -11.56 | 39.11 | 71.45 | |||||
| EPS | -1,549.90 | -151.44 | -29.04 | 16.43 | 16.43 | |||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Entero Healthcare Solutions Ltd | 162.48 | 3.87 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare ENTERO with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.16%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Feb 2024
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 5.07%
Top 5 Mutual Funds holding Entero Healthcare Solutions Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Invesco India Contra Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.6631% | Percentage of the fund’s portfolio invested in the stock 0.96% | Change in the portfolio weight of the stock over the last 3 months 0.65% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/78 (+32) |
Invesco India Smallcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8482% | Percentage of the fund’s portfolio invested in the stock 0.92% | Change in the portfolio weight of the stock over the last 3 months 0.36% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/85 (+5) |
Invesco India ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4790% | Percentage of the fund’s portfolio invested in the stock 1.03% | Change in the portfolio weight of the stock over the last 3 months 1.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 58/69 (+6) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
ENTERO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Entero Healthcare Solutions rose 360.43% to Rs 23.62 crore in the quarter ended September 2024 as against Rs 5.13 crore during the previous quarter ended September 2023. Sales rose 30.55% to Rs 1300.69 crore in the quarter ended September 2024 as against Rs 996.30 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1300.69996.30 31 OPM %3.262.87 - PBDT42.2712.75 232 PBT34.786.82 410 NP23.625.13 360 Powered by Capital Market - Live
Entero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
India Ratings and Research stated that the rating upgrade reflects continued strong growth in Entero group's scale of operations and operating profitability in FY24, with significant growth in its revenue and an improvement in the EBITDA margin and Ind-Ra's expectation of further growth in FY25 and over the medium term, backed by the heavy capital infusion into the company. In February 2024, Entero raised Rs 1,000 crore from its initial public offer (IPO) for funding expansion through acquisitions and managing its intense working capital requirement over the medium term. Backed by the unutilised amounts from the IPO proceeds, the group was net cash positive at FYE24 with a significant reduction in its overall debt levels due to the full repayment of Entero's long-term debt in March 2024. The continued expansion into newer geographies strengthening its pan-India presence and growth in customer and product portfolio during the year also support the rating. The rating is, however, constrained by the inherent limitations of distributorship and the inherent risks of the pharmaceuticals industry. The negative free cash flows since inception, and the group's brief track record of operations also constrain the rating. Entero Healthcare Solutions is a supply-chain partner and aggregator for pharmaceutical products, medical equipment, and surgical consumables. Powered by Capital Market - Live
Net profit of Entero Healthcare Solutions rose 221.79% to Rs 20.08 crore in the quarter ended June 2024 as against Rs 6.24 crore during the previous quarter ended June 2023. Sales rose 22.00% to Rs 1097.04 crore in the quarter ended June 2024 as against Rs 899.20 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1097.04899.20 22 OPM %2.752.87 - PBDT33.9112.80 165 PBT27.306.86 298 NP20.086.24 222 Powered by Capital Market - Live
Entero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Entero Healthcare Solutions announced that the Annual General Meeting (AGM) of the company will be held on 28 August 2024.Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant